2026

Bio-Neuroscience 2026 was over-subscribed. The 2027 edition is now open — and places remain strictly limited.

Feb 9 to 11, 2027

Amsterdam,
The Netherlands

Profy Countdown Timer: Visible on Live site

About

Where the Business of Neuroscience Drug Development is Done.

Exceptional, curated quality | Strictly limited places | By-invitation or application

INSIGHT • ACCESS • ENGAGEMENT • IMPACT

The Premier Gathering — By Design

Bio-Neuroscience is by-invitation in character and strictly limited in size. No filler. No noise. A handpicked assembly of the sector's top CEOs, C-suite executives, managing partners, pharma heads of business development and licensing, and the most active investors in global CNS drug development — convened in a format designed for genuine interaction, not passive attendance.

The Business of Neuroscience Drug Development

This is not a scientific conference or mass access event. It is the exclusive summit where the hottest biotech founders engage the most active neuroscience investors, where pharma business development and therapeutic area heads meet emerging and growth companies, and where the capital markets, M&A, partnering, and strategic questions that shape the sector are discussed in depth. Three days. Sustained working sessions every day. Sustained, high-quality engagement.

A Unique Level of Access — Proven

Bio-Neuroscience 2026 sold out. 2025 firmly established the format. 2024 proved the concept. Participant feedback from every edition confirms what the Advisory Board already knew: there is no comparable event. If you are building, funding, or partnering in CNS neuroscience — this is your room.

REGISTRATION CLOSED

PARTICIPANT COMMENTS

Speaking at Bio-Neuroscience was a great experience, as I had the opportunity to share insights with a select group of peers who are passionate about neuroscience advancement. The engaging discussions combined with the interactive discussions during the breaks underscored the value of the meeting.

Craig Thompson

CEO - Cerevance

Great memories from Amsterdam Bio-Neuroscience 2024! A great boutique event and the place to be for anyone with interests in translational neuroscience. Well-balanced list of selected attendees, great in-depth discussions and plenty of time for networking. The 2025 edition is getting closer and closer, looking forward to attending again.

José L. Lanciego MD, PhD

Chair - International Brain Research Organization Pan-European Committee
Senior Scientist, CNS Gene Therapy Program
Functional Neuroanatomy of the Basal Ganglia Lab, CIMA

REGISTRATION CLOSED

Vision

Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.

Drive transformational connections, discussion and partnering for startups and growth companies.

Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.

Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.

Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.

Why Now?

Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.

Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.

The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact. The 2025 edition firmly established Bio-Neuroscience as the key science - business - innovation - partnering & engagement meeting in the sector.

shutterstock_128316104 Thinking Impulses copy.jpg

MEET OUR ADVISORY BOARD

ADVISORY BOARD 2027

Robert Thorne

Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Andrea Soto Padilla

Business Development - Amsterdam UMC

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Claire Leurent

Managing Director - AbbVie Ventures

Karen LaRochelle

SVP, Global Business Development & Strategy - Merz Therapeutics

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Arno de Wilde

Managing Director - EQT Life Sciences

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Jessica Atkinson

Chief Business Officer - VectorY Therapeutics

Christian J. Suojanen

Founder & CEO - Broadreach Global,
Chairman, Bio-Neuroscience Initiative

Advisory Board

MEET THE SPEAKERS

Here are the speakers featured at Bio-Neuroscience 2026.
Check back soon for the initial 2027 lineup of leading figures from across our sector!

Ben Deverman

Senior Director, Vector Engineering, Stanley Center for Psychiatric Research - The Broad Institute of MIT and Harvard

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Stefan König

CEO - Merz Therapeutics

Keno Gutierrez

General Partner - BioGeneration Ventures (BGV)

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Henrijette Richter

Managing Partner - Sofinnova Partners

Tillmann Krüger

Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

Eric Finzi MD, PhD

Co-Founder - Healis Therapeutics

António Portela

CEO - BIAL

Jenny Laird

VP, Business Development Neuroscience - Eli Lilly

Marcelo Bigal

President and Chief Executive Officer - Ventus Therapeutics

Andrew Steinsapir

Director, Gene Therapy Program Lead - Deefield Management, & Acting CTO, Apertura Gene Therapy

Joao Barbosa da Silva

Investor - re.Mind Capital

Marco Weinberg

Senior Vice President, Head of Research - uniQure

Lynsey Bilsland

Managing Director of Parkinson's Virtual Biotech - Parkinson's UK

José Luís Lanciego

Chair – International Brain Research Organization (IBRO) Pan European
Committee, Head, Laboratory of Gene Therapy for Parkinson’s Disease – CIMA, University of Navarra

Giovanna Lalli

Director of Strategy & Operations - LifeArc

Marta Helena Lesko

VP, Head of Neurology and Immunology Business Development - Merck Group

Alex Bloom

Chief Technology Officer - AviadoBio

Yael Weiss

CEO - Mahzi Therapeutics

Christian Thomsen

Global External CNS Research - Boehringer Ingelheim

Karen LaRochelle

Global Head of Business Strategy and Portfolio Innovation - Merz Therapeutics

Vikas Sharma

Chief Business Officer - QurAlis

Claudia Persoon

Head of Neurospector - Amsterdam Neuroscience

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Kevin Sheridan

Joint Global Head of Healthcare Investment Banking - Jefferies LLC

Jing Wang

Co-Founder & Chief Executive Officer - Myrobalan Therapeutics

Opher Kornfeld

Director, Translational Research and Development - SPARK NS

Sander van Deventer

Co-Founder & President of R&D - VectorY Therapeutics

Niels Plath

Chief Scientific Officer - Muna Therapeutics

Marc Axel Wollmer, MD

Head of department, Department of Old Age Psychiatry - Asklepios Clinic North – Ochsenzoll

Violeta Stoyanova-Beninska

Senior Scientific Specialist, Office of Therapies for neurological and psychiatric disorders, &
Former Chair of Committee for Orphan Medicinal Products -
European Medicines Agency,
Chair of Regulatory Science Committee - International Rare Disease Research Consortium

Sven Pfeiffer

Partner, Strategic Advisory Group - PJT Partners

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Eric Stewart

Senior Managing Director, Healthcare Mergers & Acquisitions - Leerink Partners

Thomas Michael Thestrup

Senior Principal - Angelini Ventures

Richard Reschen

Director, Business Development & Licensing - MSD

Stuart Cobb

Chief Scientific Officer - Neurogene

2026 Agenda - Overview

Day I - 24 February 2026

14:00 - Registration Networking & Coffee

14:30 - Roundtable Sessions & Networking, with Coffee

16:00 - Program Start & Official Inauguration

18:00 - Welcome Reception

Day II - 25 February 2026

08:15 - Registration Opens

09:00 - Opening Remarks

12:45 - Networking Lunch

18:00 - End of Day & Main Networking Reception

Day III - 26 February 2026

08:15 - Registration Opens

09:00 - Start of Program

12:45 - Networking Lunch

16:15 - End of Summit Networking Reception

Note: See the most up to date version of the full 2026 Program by clicking the orange button on the program page to the right.

Click for the Program

WHO YOU'LL MEET?

Over three days of high-level plenary sessions, interactive roundtables, networking, hosted lunches and receptions — one curated group, sustained engagement.

Industry Leaders

Industry decison-makers, Heads of Therapeutic Area, Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.

Key Opinion Leaders

Key Opinion Leaders from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A.

Founders & CEOs

Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.

Government & NGOs

Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.

Investors

Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.

Patients

A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients.

Who's Coming?

Present

PRESENT YOUR COMPANY

Benefit From

Pre-summit guidance and feedback on your deck.

A pre-summit dry-run presentation with feedback.

5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In front of the full audience in the plenary session - not off in some side room!

Bio-Neuroscience offers a small number of highly innovative CNS-focused startups and growth-stage companies the opportunity to present in the main plenary session — in front of the full audience, not tucked into a side room.
Selection is by merit and scientific/commercial potential. There is no pay-to-play.

Post Pitch Meeting space to continue your Q&A, in the networking break immediately following your session.

Full access to two days of sustained engagement with investors, pharma therapeutic area and BD&L leaders, and industry decision-makers across the entire summit

Optional: dedicated poster stand to maximize visibility. For avoidance of any confusion, posters are not required and this option has no impact on selection for presentation.

PRESS RELEASE - COMPANIES SELECTED

VENUE

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in Neuroscience drug development.

HOTEL JAKARTA

Bio-Neuroscience 2027 returns to Hotel Jakarta — Amsterdam's most distinctive sustainable waterfront hotel, designed as a green oasis on the IJ river.
The venue was deliberately chosen for the way it works: intimate enough to foster genuine interaction, spacious enough for three days of ambitious programming and networking. Excellent natural light, a dedicated plenary space, and superior networking areas — purpose-suited to the boutique, high-intensity format of Bio-Neuroscience.

RESERVE YOUR HOTEL ROOM NOW

HOTEL INFO

RESERVE HERE